| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Departments of Pathology [P. S. R., D. A. C., R. C. H., M. P. B.], Medicine [S. D., R. C. H., T. A. B., M. P. B.], and Biostatistics [M. J. E.], University of Washington, Seattle, Washington 98195
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
It has been suggested that progression toward cancer in UC proceeds in a stepwise fashion of histological changes from negative for dysplasia
indefinite for dysplasia
dysplasia
cancer (4)
. Regions of cancer or HGD in UC are often surrounded by mucosa with indefinite or low-grade histology. We and others have shown that these fields of histologically abnormal mucosa are often accompanied by even larger fields of flow cytometrically detectable aneuploidy (5)
and/or regions with loss of heterozygosity and mutation of p53 (6)
. Recently, using comparative genomic hybridization (CGH), we found that approximately 40% of flow cytometrically diploid biopsies near sites of dysplasia or cancer contained clonal cell populations with subtle chromosomal abnormalities.4
These and other similar findings suggested the possibility that CIN is an early step in neoplastic progression in UC. To pursue this question, we used dual-color FISH with paired green fluorescent centromere probes and red fluorescent arm probes on four different chromosomes. FISH can identify CIN in small subpopulations of interphase cells (7)
, allowing the detection of infrequent, possibly random changes before they lead to clonal expansion. These experiments demonstrate that CIN is present throughout the colon of patients with dysplasia or cancer in UC.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell Preparation.
Epithelial cells were isolated from biopsies by the following method: the nonmucosal side of biopsy specimens was affixed to the end of a 2.5-mm-diameter stick with cyanoacrylate glue and soaked for 5 min in Hanks buffer with 20 mM DTT and 5 mM EDTA at 37°C. Samples were transferred to 2 ml of shaking solution (Hanks buffer with 20 mM DTT, 5 mM CaCl2, 5 mM MgCl2, and 10% DMSO at 4°C) and vortexed for 5 s, and then the stick with residual stroma was removed. Staining with anticytokeratin antibody showed that the cells in suspension at the end of this procedure were >90% epithelial.
FISH.
Cells were washed in 5 mM CaCl2 with 0.1% NP40, spun (10 min at 1000 x g), washed again in 1 ml of 5 mM CaCl2 with 200 µl chilled 3:1 methanol:acetic acid, and spun. Ten µl of nuclear suspension were dropped on plain glass slides and fixed with 3:1 methanol:acetic acid, followed by 1% paraformaldehyde. Replicate slides from each biopsy were hybridized to pairs of FITC-labeled centromere and TRITC-labeled locus-specific probes for chromosomes 8, 11, 17, and 18: (a) D8Z2 (centromere), 8q21.3, D18Z1 (centromere), and 18q21.2 (Oncor, Inc., Gaithersburg, MD); and (b) p53 (17p13.1), 17
(centromere), cyclin D1 (11q.13), and 11 SG (centromere; Vysis, Inc., Downers Grove, IL). For simplicity, analyses from spectrum orange labeled locus-specific probes on chromosomal arms are referred to as analyses of chromosomal arms. Slides were dehydrated in 70%, 85%, and 100% ethanol at 22°C; denatured in 70% formamide at 72°C; dehydrated in 70%, 85%, and 100% ethanol at -20°C, and incubated overnight with the probe pairs described above. Slides were then washed in 2 x SSC at 72°C and 2 x SSC with 0.03% Tween (pH 5.3). Cells were covered with Anti-fade (Oncor, Inc.) containing 0.25 ng/µl diamindino-2-phenyl indole (Sigma), and slides were examined at x100 under oil using an epifluorescence microscope equipped with a Hamamatsu C5810 charge-coupled device camera. For each sample and pair of probes, the number of red and green FISH spots was counted for 100 ± 6 nuclei (mean ± SD) by an observer blinded to the sample identity. Counting was repeated blindly on a subset of samples to evaluate reproducibility, which was determined to be within the expected statistical error.
Statistics.
Differences in frequencies of abnormalities were estimated and tested for statistical significance using a marginal generalized linear model for cluster correlated data with an independence working correlation matrix and its associated generalized Wald test (9)
. An overdisperison parameter was included in the marginal model (10)
. The generalized Wald test was also used to test for differences in the patterns of FISH abnormalities. This test is similar to the commonly used
2 test for association between two categorical variables (11)
, but it also accounts for dependencies between observations from the same person. Abnormality categories with low expected counts were excluded for the last analysis.
ROCs were analyzed to determine the sensitivity and specificity of various FISH abnormalities to distinguish individual histologically negative rectal UC biopsies from control biopsies (11) . The ROC shows that the trade off between sensitivity and specificity as the threshold for defining a "positive test" is varied. For ROC results based on more than one chromosome, the percentage of FISH abnormalities was calculated by pooling the counts over the chromosomes. The optimal cutoff was determined as that corresponding to the ROC point closest to the upper left corner of the plot. Cutoffs differ, depending on the abnormality.
| RESULTS |
|---|
|
|
|---|
|
|
Chromosomal arm losses appeared more likely in early neoplastic progression, whereas gains more commonly occurred later (Fig. 1, e and f)
. Chromosomal arm losses were significantly more frequent in NegR (P < 10-4) and Neg (P = 0.0001) UC biopsies than in non-UC control biopsies. However, losses of chromosomal arms did not increase further in biopsies with dysplasia or cancer. Loss of arms in UC appears to be chromosome specific: chromosome 8 was much less likely to have arm losses than chromosomes 11 or 18 (P < 10-13); and chromosome 17 was more likely to have arm losses than chromosomes 11 or 18 (P < 0.02).
Gain of chromosomal arms was not as good a discriminator of changes in NegR UC biopsies as was loss of arms (note the difference in confidence intervals between Fig. 1e and 1f
; see Table 1
); however, the probabilities of chromosomal arm gains increased further in HGD and cancer (Fig. 1e)
. Chromosome 17 showed fewer arm gains than did the other chromosomes (P < 0.01).
|
Patterns of FISH Abnormalities.
The comparisons above address differences in the frequencies of classes of FISH abnormalities (e.g., any abnormality, abnormal arm counts, and abnormal centromere counts). We also addressed the question of whether the distribution of specific abnormal FISH counts, as shown in Fig. 2
, differed between chromosome probes. (It is possible, for example, for the frequencies of any abnormality to be the same for two chromosomes while the distributions [patterns] over the specific abnormalities differ). We used the Wald test (see "Materials and Methods") to examine differences in the pattern of abnormalities between chromosomes within the NegR category, and to examine differences in the patterns of abnormalities in NegR versus non-UC samples. Within NegR biopsies, the distributions of abnormalities for chromosomes 17 versus 11, 17 versus 18, and 11 versus 18 were all different from each other (P = 0.002, P < 10-8, and P = 0.0002, respectively). The distribution of abnormalities was different in NegR versus non-UC controls within chromosomes 11 (P < 10-10) and 17 (P < 10-8).
Fig. 2
illustrates that the most significant abnormality in NegR biopsies was arm losses (1 arm-2 centromeres and 0 arm-2 centromeres), especially in chromosome 17, where 9% of NegR cells had loss of one arm of 17p, and 5% of cells had loss of both arms of 17p. As suggested by Fig. 1f
, these arm losses did not increase further with increasing histological grade. Consistent with Fig. 1g
, Fig. 2
also shows a pattern of increasing frequencies of centromere gains (0a3c, 2a3c, and 2a4c) in HGD and CA.
Sensitivity and Specificity of FISH Findings.
The sensitivity and specificity of FISH abnormalities for distinguishing individual NegR UC biopsies from control biopsies were determined from ROCs see ("Materials and Methods"). Sensitivity in this context refers to the probability of a positive test result in an individual UC biopsy. Specificity refers to the probability that the test is negative in a control biopsy. Table 1
shows the optimum combinations of sensitivity and specificity derived from these curves. When the category of any FISH abnormality was considered, optimum sensitivity and specificity for separating individual NegR UC biopsies from control biopsies was derived from the analysis of chromosomes 11, 17, and 18, consistent with the results shown in Fig. 1
. The ROC analysis also showed that centromere counts are not as sensitive or specific as arm counts for discriminating NegR UC from non-UC controls. In fact, arm counts from the combination of chromosomes 11, 17, and 18 fully separated individual NegR UC biopsies from control biopsies (sensitivity and specificity = 1.0): all NegR biopsies had more than 11% abnormal counts for pooled chromosome 11, 17, and 18 arm markers; and all controls had less than this. Arm counts from chromosome 17 alone were almost as good (sensitivity and specificity = 0.9; Table 1
). Consistent with Fig. 1
, arm losses were much better discriminators than gains.
| DISCUSSION |
|---|
|
|
|---|
High rates of CIN have previously been found in aneuploid colon cancer cell lines and been termed the CIN phenotype (7)
. The frequency of FISH abnormalities that we observe in UC cancer and HGD are similar to those reported previously in CIN cell lines. Diploid colon cancer cell lines are not reported to show this phenotype but are typically deficient in DNA mismatch repair, leading to the microsatellite instability phenotype (7
, 15)
. We observe more FISH abnormalities in diploid UC biopsies that are Neg and IND than have been reported for diploid (microsatellite instability) cancer cell lines, suggesting that the preneoplastic cells in UC exhibit the CIN phenotype well before aneuploidy develops. Flow cytometric aneuploidy was present in two of seven Neg, one of four HGD, and three of four cancer biopsies. When aneuploid biopsies were removed from the analysis, no differences in overall trends were observed, except that the probability of FISH abnormalities was lower in the one diploid cancer biopsy (data not shown). Notably, the finding of increasing probabilities of FISH abnormalities in higher grades of dysplasia and more frequent centromere and arm gains, rather than losses, in dysplastic as compared to negative biopsies (Fig. 1)
persisted in diploid samples. We suggest that this progression is a feature of the developing CIN phenotype in UC and that aneuploidy is a secondary event.
Although the FISH methodology is subject to some counting errors (for example, overlapping FISH spots counted as one), these are expected to be similar in control and UC samples. On average, 11% more cells in NegR UC biopsies and 19% more cells from Neg UC biopsies near dysplasia or cancer showed FISH abnormalities than controls (Fig. 1a
,
). Loss of one or more copies of 17p was the single most common abnormality in NegR UC biopsies; it was present in 10.5% more cells than in controls (Figs. 1a
and 2
). Almost half of this excess (4.7%) involved loss of both short arms of chromosome 17 (Fig. 2)
; loss of both copies of p53 would, by itself, be considered a contribution to cancer risk. If the four chromosomes measured in this report were typical, each cell in the rectal UC biopsies would have, on average, almost three chromosomal aberrations. Because these may not be clonal, they might not necessarily involve the crypt stem cells, in which case, chromosomal aberrations would have to be accumulated at high frequency as the cells move up from the crypt base to surface, where they are sloughed. Measuring chromosomal abnormalities as a function of location in the crypt would require FISH on histological sections; this method, however, yields frequent artifacts due to cut and overlapping nuclei (16)
.
The high rates of CIN in histologically negative UC epithelium suggest that UC colonocytes are subject to high rates of genetic damage, chromosomal breakage, mitotic infidelity, or all three. UC has been associated with elevated levels of reactive oxygen species and reduced oxidative defenses, both of which might contribute to genetic damage (17, 18, 19, 20) . Telomeres have been reported to be shortened in histologically negative UC biopsies (21) , presumably because of both higher proliferative rates and increased oxidative damage in UC.
Because one function of telomeres is to reduce the fusigenic potential of chromosome ends, shortened telomeres can contribute to CIN via end-to-end chromosome fusion and consequent nondisjunction or bridge-breakage-fusion (22) . In fact, 17p has been reported to have the shortest telomeres of any human chromosome (23) ; although speculative, this might be consistent with our observation that the highest rates of chromosomal arm loss were on 17p. Abnormalities in the fidelity of the mitotic apparatus have been suggested to be important in sporadic colon cancer, including damage to mitotic checkpoints (24) . Whereas the high frequency of observed CIN would require improbably high mutation rates in mitotic regulatory or structural genes, it is possible that epigenetic changes, such as methylation, could adversely affect the genes responsible for mitotic fidelity. Overexpression of pericentrin, for example, is frequent in cancers and can result in chromosome missegregation and breakage (25) .
The ability of FISH to distinguish individual NegR UC biopsies (obtained from patients with dysplasia or cancer elsewhere in their colon) from controls with 100% sensitivity and specificity using three probes (11q, 17p, and 18q; Table 1
) suggests that risk assessment of individuals may be possible by FISH analysis of rectal biopsies. In a preliminary study of eight UC patients who have not developed dysplasia over an average 15-year duration of disease, FISH counts for chromosomes 17 and 11 were no different than those seen in non-UC controls (P = 0.36 and 0.73, respectively) and were very different from NegR biopsies in patients with HGD or cancer (P < 0.0001).5
Because we studied UC patients in this report only at the time of diagnosis of dysplasia or cancer, it remains to be proven that CIN can be similarly detected preceding dysplasia and cancer in UC; however, this would be most consistent with both the pancolonic distribution of CIN that we observed and the hypothesis that the process of CIN underlies progression to cancer. If FISH examination of rectal biopsies can indeed identify the subset of UC patients at risk for dysplasia or cancer, this could have considerable impact on the medical management of these patients. It would also give strong impetus to the development of therapeutic strategies to reduce CIN before it progresses to dysplasia or cancer.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported by grants from the Crohns and Colitis Foundation of America and NIH Grants R01CA68124, P01CA74184, and R29CA77607. ![]()
2 To whom requests for reprints should be addressed, at Department of Pathology, Box 357707, University of Washington, Seattle, WA 98195. Fax: (206) 616-8271; E-mail: petersr{at}u.washington.edu ![]()
3 The abbreviations used are: UC, ulcerative colitis; FISH, fluorescence in situ hybridization; HGD, high-grade dysplasia; CIN, chromosomal instability; LGD, low-grade dysplasia; IND, indefinite for dysplasia; Neg, negative for dysplasia; ROC, receiver operator curve; NegR, rectal biopsies negative for dysplasia; CGH, comparative genomic hybridization. ![]()
4 Robert F. Willenbucher, Peter Rabinovitch, Daniela E. Aust, Teresa Brentnall, Suzanne J. Zelman, Roger Haggitt, and Frederic M. Waldman. Ulcerative colitis-related dysplasia arises in a genetically abnormal nondysplastic epithelium, submitted for publication. ![]()
Received 3/16/99. Accepted 8/19/99.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E Burum-Auensen, P M DeAngelis, A R Schjolberg, J. Roislien, S N Andersen, and O P F Clausen Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis J. Clin. Pathol., December 1, 2007; 60(12): 1403 - 1408. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Masramon, E. Vendrell, G. Tarafa, G. Capella, R. Miro, M. Ribas, and M. A. Peinado Genetic instability and divergence of clonal populations in colon cancer cells in vitro J. Cell Sci., April 15, 2006; 119(8): 1477 - 1482. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O'Sullivan, R. A. Risques, M. T. Mandelson, L. Chen, T. A. Brentnall, M. P. Bronner, M. P. MacMillan, Z. Feng, J. R. Siebert, J. D. Potter, et al. Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 573 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Fujii, K Tominaga, K Kitajima, J Takeda, T Kusaka, M Fujita, K Ichikawa, S Tomita, Y Ohkura, Y Ono, et al. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis Gut, September 1, 2005; 54(9): 1287 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chen, P. S. Rabinovitch, D. A. Crispin, M. J. Emond, M. P. Bronner, and T. A. Brentnall The initiation of colon cancer in a chronic inflammatory setting Carcinogenesis, September 1, 2005; 26(9): 1513 - 1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mitomi, I. Okayasu, M. P. Bronner, H. Kanazawa, Y. Nishiyama, Y. Otani, M. Sada, S. Tanabe, M. Igarashi, T. Katsumata, et al. Comparative Histologic Assessment of Proctocolectomy Specimens from Japanese and American Patients with Ulcerative Colitis with or Without Dysplasia International Journal of Surgical Pathology, July 1, 2005; 13(3): 259 - 265. [Abstract] [PDF] |
||||
![]() |
R. E. Rudolph, J. A. Dominitz, J. W. Lampe, L. Levy, P. Qu, S. S. Li, P. D. Lampe, M. P. Bronner, and J. D. Potter Risk Factors for Colorectal Cancer in Relation to Number and Size of Aberrant Crypt Foci in Humans Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 605 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. El-Zein, Y. Gu, M. S. Sierra, M. R. Spitz, and S. S. Strom Chromosomal Instability in Peripheral Blood Lymphocytes and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 748 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-e- Khuda, M. Yoshida, Y. Xing, T. Shimasaki, M. Takeya, K. Kuwahara, and N. Sakaguchi The Sac3 Homologue shd1 Is Involved in Mitotic Progression in Mammalian Cells J. Biol. Chem., October 29, 2004; 279(44): 46182 - 46190. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Itzkowitz and X. Yio Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-K. Lin, S.-C. Chang, Y.-C. Yang, and A. F.-Y. Li Loss of Heterozygosity and DNA Aneuploidy in Colorectal Adenocarcinoma Ann. Surg. Oncol., November 1, 2003; 10(9): 1086 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Barrett, D. Pritchard, C. Palanca-Wessels, J. Anderson, B. J. Reid, and P. S. Rabinovitch Molecular Phenotype of Spontaneously Arising 4N (G2-Tetraploid) Intermediates of Neoplastic Progression in Barrett's Esophagus Cancer Res., July 15, 2003; 63(14): 4211 - 4217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. A. Palanca-Wessels, A. Klingelhutz, B. J. Reid, T. H. Norwood, K. E. Opheim, T. G. Paulson, Z. Feng, and P. S. Rabinovitch Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model Carcinogenesis, July 1, 2003; 24(7): 1183 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chen, P. S. Rabinovitch, D. A. Crispin, M. J. Emond, K. M. Koprowicz, M. P. Bronner, and T. A. Brentnall DNA Fingerprinting Abnormalities Can Distinguish Ulcerative Colitis Patients with Dysplasia and Cancer from Those Who Are Dysplasia/Cancer-Free Am. J. Pathol., February 1, 2003; 162(2): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Engle, I. Ormsby, S. Pawlowski, G. P. Boivin, J. Croft, E. Balish, and T. Doetschman Elimination of Colon Cancer in Germ-free Transforming Growth Factor Beta 1-deficient Mice Cancer Res., November 15, 2002; 62(22): 6362 - 6366. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fukushima, N. Sato, T. Ueki, C. Rosty, K. M. Walter, R. E. Wilentz, C. J. Yeo, R. H. Hruban, and M. Goggins Aberrant Methylation of Preproenkephalin and p16 Genes in Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma Am. J. Pathol., May 1, 2002; 160(5): 1573 - 1581. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. J. Issa, N. Ahuja, M. Toyota, M. P. Bronner, and T. A. Brentnall Accelerated Age-related CpG Island Methylation in Ulcerative Colitis Cancer Res., May 1, 2001; 61(9): 3573 - 3577. [Abstract] [Full Text] |
||||
![]() |
L. A. Loeb A Mutator Phenotype in Cancer Cancer Res., April 1, 2001; 61(8): 3230 - 3239. [Abstract] [Full Text] |
||||
![]() |
S. N. Agoff, T. A. Brentnall, D. A. Crispin, S. L. Taylor, S. Raaka, R. C. Haggitt, M. W. Reed, I. A. Afonina, P. S. Rabinovitch, A. C. Stevens, et al. The Role of Cyclooxygenase 2 in Ulcerative Colitis-Associated Neoplasia Am. J. Pathol., September 1, 2000; 157(3): 737 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Hussain, P. Amstad, K. Raja, S. Ambs, M. Nagashima, W. P. Bennett, P. G. Shields, A.-J. Ham, J. A. Swenberg, A. J. Marrogi, et al. Increased p53 Mutation Load in Noncancerous Colon Tissue from Ulcerative Colitis: A Cancer-prone Chronic Inflammatory Disease Cancer Res., July 1, 2000; 60(13): 3333 - 3337. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |